Bradford J Shafer Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Bradford J Shafer.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Bradford J Shafer. Bradford J Shafer is Sr VP, Gen. Counsel, Secretary in Innoviva, Inc. ($THRX) and EVP, Gen. Counsel, Secretary in Theravance Biopharma, Inc. ($TBPH) and Sr VP, Gen. Counsel, Secretary in Theravance Biopharma, Inc. ($TBPH).
Latest Insider Trading Transactions of Bradford J Shafer
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 24 2021 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 17.80 | 4,310 | 76,718 | 282,138 | 286.4 K to 282.1 K (-1.50 %) |
| Feb 10 2021 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 316,916 | 251.9 K to 316.9 K (+25.80 %) |
| Aug 24 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 18.22 | 4,804 | 87,529 | 256,723 | 261.5 K to 256.7 K (-1.84 %) |
| May 22 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 26.67 | 4,807 | 128,203 | 261,527 | 266.3 K to 261.5 K (-1.80 %) |
| Feb 24 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 25.90 | 29,402 | 761,512 | 264,932 | 294.3 K to 264.9 K (-9.99 %) |
| Feb 05 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 54,000 | 0 | 294,334 | 240.3 K to 294.3 K (+22.47 %) |
| Feb 05 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 240,334 | 175.3 K to 240.3 K (+37.07 %) |
| Aug 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 21.51 | 3,084 | 66,337 | 178,901 | 182 K to 178.9 K (-1.69 %) |
| May 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 19.84 | 2,488 | 49,362 | 181,985 | 184.5 K to 182 K (-1.35 %) |
| Feb 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 27.00 | 5,798 | 156,546 | 183,446 | 189.2 K to 183.4 K (-3.06 %) |
| Feb 07 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 47,250 | 0 | 189,244 | 142 K to 189.2 K (+33.28 %) |
| Feb 07 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 141,994 | 77 K to 142 K (+84.42 %) |
| Nov 21 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 24.79 | 7,006 | 173,679 | 76,994 | 84 K to 77 K (-8.34 %) |
| Aug 29 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 27.71 | 7,119 | 197,282 | 84,000 | 91.1 K to 84 K (-7.81 %) |
| Aug 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 26.95 | 7,005 | 188,785 | 91,119 | 98.1 K to 91.1 K (-7.14 %) |
| Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 27.85 | 25,355 | 706,182 | 98,124 | 123.5 K to 98.1 K (-20.53 %) |
| Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.03 | 4,127 | 115,686 | 123,479 | 127.6 K to 123.5 K (-3.23 %) |
| Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.99 | 1,818 | 52,707 | 127,606 | 129.4 K to 127.6 K (-1.40 %) |
| Jun 08 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 23.66 | 3,900 | 92,260 | 129,424 | 133.3 K to 129.4 K (-2.93 %) |
| Jun 08 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 24.09 | 10,140 | 244,268 | 133,324 | 143.5 K to 133.3 K (-7.07 %) |
| May 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 24.31 | 21,812 | 530,250 | 143,464 | 165.3 K to 143.5 K (-13.20 %) |
| May 16 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 33,750 | 0 | 165,276 | 131.5 K to 165.3 K (+25.66 %) |
| Feb 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 29.09 | 5,587 | 162,526 | 130,661 | 136.2 K to 130.7 K (-4.10 %) |
| Feb 14 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 9,000 | 0 | 136,248 | 127.2 K to 136.2 K (+7.07 %) |
| Nov 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 28.58 | 7,079 | 202,318 | 127,248 | 134.3 K to 127.2 K (-5.27 %) |
| Sep 08 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 30.77 | 14,670 | 451,350 | 134,327 | 149 K to 134.3 K (-9.85 %) |
| Aug 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 27.40 | 7,079 | 193,965 | 148,997 | 156.1 K to 149 K (-4.54 %) |
| May 23 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 36.83 | 7,079 | 260,720 | 156,076 | 163.2 K to 156.1 K (-4.34 %) |
| Mar 07 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 31.86 | 26,829 | 854,772 | 161,453 | 188.3 K to 161.5 K (-14.25 %) |
| Feb 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 33.78 | 12,440 | 420,223 | 188,282 | 200.7 K to 188.3 K (-6.20 %) |
| Feb 08 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 9,000 | 0 | 200,722 | 191.7 K to 200.7 K (+4.69 %) |
| Nov 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 31.96 | 4,008 | 128,096 | 191,722 | 195.7 K to 191.7 K (-2.05 %) |
| Aug 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 27.16 | 37,078 | 1,007,038 | 195,730 | 232.8 K to 195.7 K (-15.93 %) |
| Aug 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 27.89 | 4,008 | 111,783 | 232,808 | 236.8 K to 232.8 K (-1.69 %) |
| Aug 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.14 | 4,870 | 137,042 | 236,816 | 241.7 K to 236.8 K (-2.02 %) |
| Aug 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.55 | 7,174 | 204,818 | 241,686 | 248.9 K to 241.7 K (-2.88 %) |
| May 24 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 20.55 | 4,008 | 82,364 | 248,860 | 252.9 K to 248.9 K (-1.59 %) |
| Mar 17 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 115,000 | 0 | 251,165 | 136.2 K to 251.2 K (+84.46 %) |
| Feb 23 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 15.65 | 18,920 | 296,098 | 136,165 | 155.1 K to 136.2 K (-12.20 %) |
| Nov 24 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 17.17 | 934 | 16,037 | 155,085 | 156 K to 155.1 K (-0.60 %) |
| Aug 24 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 12.98 | 934 | 12,123 | 156,019 | 157 K to 156 K (-0.60 %) |
| Jun 04 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 13.83 | 7,360 | 101,789 | 156,953 | 164.3 K to 157 K (-4.48 %) |
| May 22 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 14.24 | 673 | 9,584 | 164,313 | 165 K to 164.3 K (-0.41 %) |
| Feb 24 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 19.52 | 674 | 13,156 | 163,088 | 163.8 K to 163.1 K (-0.41 %) |
| Jun 04 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 21,000 | 0 | 412,398 | 391.4 K to 412.4 K (+5.37 %) |
| Jun 04 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 50,000 | 0 | 391,398 | 341.4 K to 391.4 K (+14.65 %) |
| May 12 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 26.86 | 22,833 | 613,294 | 341,398 | 364.2 K to 341.4 K (-6.27 %) |
| Apr 29 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 37,500 | 0 | 364,231 | 326.7 K to 364.2 K (+11.48 %) |
| Mar 05 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Option Exercise | M | 9.69 | 65,806 | 637,496 | 0 | |
| Mar 05 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Option Exercise | M | 9.69 | 30,967 | 299,993 | 0 | |
| Mar 05 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 37.23 | 1,800 | 67,014 | 326,731 | 328.5 K to 326.7 K (-0.55 %) |
| Mar 05 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 36.72 | 64,006 | 2,350,300 | 328,531 | 392.5 K to 328.5 K (-16.31 %) |
| Mar 05 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Buy | M | 9.69 | 65,806 | 637,496 | 392,537 | 326.7 K to 392.5 K (+20.14 %) |
| Mar 05 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Buy | M | 9.69 | 30,967 | 299,993 | 326,731 | 295.8 K to 326.7 K (+10.47 %) |
| Feb 24 2014 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 39.98 | 4,310 | 172,314 | 295,764 | 300.1 K to 295.8 K (-1.44 %) |
| Nov 22 2013 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 36.40 | 4,569 | 166,312 | 300,074 | 304.6 K to 300.1 K (-1.50 %) |
| Aug 22 2013 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 35.89 | 3,773 | 135,413 | 304,643 | 308.4 K to 304.6 K (-1.22 %) |
| Jul 26 2013 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 5,000 | 0 | 308,416 | 303.4 K to 308.4 K (+1.65 %) |
| Jun 11 2013 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 35.04 | 31,038 | 1,087,572 | 303,416 | 334.5 K to 303.4 K (-9.28 %) |
| May 22 2013 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 37.01 | 3,292 | 121,837 | 334,454 | 337.7 K to 334.5 K (-0.97 %) |
| Feb 22 2013 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 22.10 | 5,004 | 110,588 | 337,746 | 342.8 K to 337.7 K (-1.46 %) |
| Feb 11 2013 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 5,000 | 0 | 342,750 | 337.8 K to 342.8 K (+1.48 %) |
| Nov 20 2012 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 21.08 | 4,874 | 102,744 | 337,750 | 342.6 K to 337.8 K (-1.42 %) |
| Oct 17 2012 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 5,000 | 0 | 342,624 | 337.6 K to 342.6 K (+1.48 %) |
| Aug 22 2012 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 27.01 | 4,596 | 124,138 | 337,624 | 342.2 K to 337.6 K (-1.34 %) |
| May 22 2012 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 20.33 | 3,832 | 77,905 | 342,220 | 346.1 K to 342.2 K (-1.11 %) |
| Feb 22 2012 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 18.54 | 9,621 | 178,373 | 346,052 | 355.7 K to 346.1 K (-2.71 %) |
| Feb 17 2012 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 5,000 | 0 | 355,673 | 350.7 K to 355.7 K (+1.43 %) |
| Nov 30 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Option Exercise | M | 8.53 | 16,129 | 137,580 | 0 | |
| Nov 30 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Option Exercise | M | 8.53 | 14,076 | 120,068 | 0 | |
| Nov 30 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 21.00 | 20,000 | 420,000 | 350,673 | 370.7 K to 350.7 K (-5.40 %) |
| Nov 30 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Buy | M | 8.53 | 16,129 | 137,580 | 370,673 | 354.5 K to 370.7 K (+4.55 %) |
| Nov 30 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Buy | M | 8.53 | 14,076 | 120,068 | 354,544 | 340.5 K to 354.5 K (+4.13 %) |
| Nov 22 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 22.34 | 2,121 | 47,383 | 340,468 | 342.6 K to 340.5 K (-0.62 %) |
| Aug 23 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 17.50 | 2,120 | 37,100 | 342,589 | 344.7 K to 342.6 K (-0.62 %) |
| May 24 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 25.48 | 2,116 | 53,916 | 344,709 | 346.8 K to 344.7 K (-0.61 %) |
| Mar 15 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 22.75 | 6,451 | 146,760 | 0 | 6.5 K to 0 (-100.00 %) |
| Mar 15 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 22.76 | 20,238 | 460,617 | 346,825 | 367.1 K to 346.8 K (-5.51 %) |
| Feb 23 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 22.50 | 3,111 | 69,998 | 367,063 | 370.2 K to 367.1 K (-0.84 %) |
| Feb 15 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 100,000 | 0 | 370,174 | 270.2 K to 370.2 K (+37.01 %) |
| Feb 15 2011 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 12,500 | 0 | 270,174 | 257.7 K to 270.2 K (+4.85 %) |
| Nov 23 2010 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 22.52 | 2,403 | 54,116 | 257,674 | 260.1 K to 257.7 K (-0.92 %) |
| Oct 28 2010 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 12,500 | 0 | 260,077 | 247.6 K to 260.1 K (+5.05 %) |
| Aug 23 2010 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 14.00 | 1,543 | 21,602 | 247,577 | 249.1 K to 247.6 K (-0.62 %) |
| May 21 2010 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 13.02 | 1,544 | 20,103 | 249,120 | 250.7 K to 249.1 K (-0.62 %) |
| Feb 23 2010 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 10.22 | 1,163 | 11,886 | 250,664 | 251.8 K to 250.7 K (-0.46 %) |
| Feb 12 2010 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 25,000 | 0 | 251,827 | 226.8 K to 251.8 K (+11.02 %) |
| Nov 24 2009 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 14.04 | 971 | 13,633 | 226,827 | 227.8 K to 226.8 K (-0.43 %) |
| Aug 21 2009 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 15.65 | 946 | 14,805 | 227,798 | 228.7 K to 227.8 K (-0.41 %) |
| May 22 2009 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 14.06 | 946 | 13,301 | 228,744 | 229.7 K to 228.7 K (-0.41 %) |
| Mar 24 2009 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 37,000 | 0 | 229,690 | 192.7 K to 229.7 K (+19.20 %) |
| Feb 24 2009 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 14.87 | 578 | 8,595 | 192,690 | 193.3 K to 192.7 K (-0.30 %) |
| Aug 01 2008 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 15.97 | 34,676 | 553,689 | 193,268 | 227.9 K to 193.3 K (-15.21 %) |
| Jan 31 2008 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Grant | A | 0.00 | 5,376 | 0 | 227,944 | 222.6 K to 227.9 K (+2.42 %) |
| Nov 02 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.00 | 25,000 | 625,000 | 222,568 | 247.6 K to 222.6 K (-10.10 %) |
| Nov 02 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Buy | W | 0.00 | 833 | 0 | 247,568 | 246.7 K to 247.6 K (+0.34 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.55 | 100 | 2,555 | 246,735 | 246.8 K to 246.7 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.57 | 100 | 2,557 | 246,835 | 246.9 K to 246.8 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.61 | 200 | 5,122 | 246,935 | 247.1 K to 246.9 K (-0.08 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.63 | 100 | 2,563 | 247,135 | 247.2 K to 247.1 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.66 | 400 | 10,264 | 247,235 | 247.6 K to 247.2 K (-0.16 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.67 | 200 | 5,134 | 247,635 | 247.8 K to 247.6 K (-0.08 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.68 | 100 | 2,568 | 247,835 | 247.9 K to 247.8 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.71 | 300 | 7,713 | 247,935 | 248.2 K to 247.9 K (-0.12 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.73 | 300 | 7,719 | 248,235 | 248.5 K to 248.2 K (-0.12 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.75 | 500 | 12,875 | 248,535 | 249 K to 248.5 K (-0.20 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.76 | 300 | 7,728 | 249,035 | 249.3 K to 249 K (-0.12 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.77 | 100 | 2,577 | 249,335 | 249.4 K to 249.3 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.78 | 100 | 2,578 | 249,435 | 249.5 K to 249.4 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.79 | 900 | 23,211 | 249,535 | 250.4 K to 249.5 K (-0.36 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.80 | 500 | 12,900 | 250,435 | 250.9 K to 250.4 K (-0.20 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.81 | 100 | 2,581 | 250,935 | 251 K to 250.9 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.82 | 600 | 15,492 | 251,035 | 251.6 K to 251 K (-0.24 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.83 | 400 | 10,332 | 251,635 | 252 K to 251.6 K (-0.16 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.84 | 200 | 5,168 | 252,035 | 252.2 K to 252 K (-0.08 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.85 | 200 | 5,170 | 252,235 | 252.4 K to 252.2 K (-0.08 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.86 | 600 | 15,516 | 252,435 | 253 K to 252.4 K (-0.24 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.87 | 452 | 11,693 | 253,035 | 253.5 K to 253 K (-0.18 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.88 | 700 | 18,116 | 253,487 | 254.2 K to 253.5 K (-0.28 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.89 | 1,300 | 33,657 | 254,187 | 255.5 K to 254.2 K (-0.51 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.90 | 2,048 | 53,043 | 255,487 | 257.5 K to 255.5 K (-0.80 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.91 | 400 | 10,364 | 257,535 | 257.9 K to 257.5 K (-0.16 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.92 | 300 | 7,776 | 257,935 | 258.2 K to 257.9 K (-0.12 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.93 | 500 | 12,965 | 258,235 | 258.7 K to 258.2 K (-0.19 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.94 | 1,400 | 36,316 | 258,735 | 260.1 K to 258.7 K (-0.54 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.95 | 1,000 | 25,950 | 260,135 | 261.1 K to 260.1 K (-0.38 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.96 | 1,673 | 43,431 | 261,135 | 262.8 K to 261.1 K (-0.64 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.97 | 500 | 12,985 | 262,808 | 263.3 K to 262.8 K (-0.19 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.98 | 300 | 7,794 | 263,308 | 263.6 K to 263.3 K (-0.11 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 25.99 | 827 | 21,494 | 263,608 | 264.4 K to 263.6 K (-0.31 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.00 | 1,600 | 41,600 | 264,435 | 266 K to 264.4 K (-0.60 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.01 | 1,000 | 26,010 | 266,035 | 267 K to 266 K (-0.37 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.02 | 600 | 15,612 | 267,035 | 267.6 K to 267 K (-0.22 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.03 | 100 | 2,603 | 267,635 | 267.7 K to 267.6 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.24 | 200 | 5,248 | 267,735 | 267.9 K to 267.7 K (-0.07 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.26 | 100 | 2,626 | 267,935 | 268 K to 267.9 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.28 | 100 | 2,628 | 268,035 | 268.1 K to 268 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.29 | 300 | 7,887 | 268,135 | 268.4 K to 268.1 K (-0.11 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.30 | 400 | 10,520 | 268,435 | 268.8 K to 268.4 K (-0.15 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.32 | 100 | 2,632 | 268,835 | 268.9 K to 268.8 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.33 | 100 | 2,633 | 268,935 | 269 K to 268.9 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.38 | 200 | 5,276 | 269,035 | 269.2 K to 269 K (-0.07 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.44 | 100 | 2,644 | 269,235 | 269.3 K to 269.2 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.46 | 500 | 13,230 | 269,335 | 269.8 K to 269.3 K (-0.19 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.48 | 200 | 5,296 | 269,835 | 270 K to 269.8 K (-0.07 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.49 | 100 | 2,649 | 270,035 | 270.1 K to 270 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.52 | 100 | 2,652 | 270,135 | 270.2 K to 270.1 K (-0.04 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.54 | 200 | 5,308 | 270,235 | 270.4 K to 270.2 K (-0.07 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.55 | 200 | 5,310 | 270,435 | 270.6 K to 270.4 K (-0.07 %) |
| Aug 03 2007 | THRX | Innoviva, Inc. | Shafer Bradford J | Sr VP, Gen. Counsel ... | Sell | S | 26.59 | 100 | 2,659 | 270,635 | 270.7 K to 270.6 K (-0.04 %) |